10x Genomics: Q4 Earnings Insights
Portfolio Pulse from Benzinga Insights
10x Genomics (NASDAQ:TXG) reported Q4 earnings with a 33.33% beat on estimated EPS, reporting an EPS of $-0.24 versus an estimate of $-0.36. Revenue increased by $27.75 million from the same period last year. The company had previously beaten EPS estimates last quarter, which led to an 8.73% increase in share price the following day.
February 15, 2024 | 9:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
10x Genomics reported a significant beat on Q4 earnings estimates and showcased revenue growth from the previous year.
The significant beat on earnings estimates and the historical context of share price increase following earnings beats suggest a positive short-term impact on TXG's stock price. The company's consistent performance in beating revenue and EPS estimates could increase investor confidence and potentially lead to a rise in stock price, similar to the 8.73% increase observed in the previous quarter.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100